Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR9614755Aexternal-prioritypatent/FR2756493B1/en
Application filed by Sod Conseils Rech ApplicfiledCriticalSod Conseils Rech Applic
Publication of NZ510931ApublicationCriticalpatent/NZ510931A/en
A solid delayed-release formulation, intended to be placed in a body, containing at least one active principle and a biodegradable excipient, wherein the excipient is a polyactide-glycolide (PLGA) copolymer, the concentration of the active principle is over 40% and the excipient does not form a matrix containing the active principle, whereby the release profile of the active principle is constant and the duration of release is substantially greater in vivo than in physiological aqueous medium in vitro. A process of preparation of this delayed-release formulation is also described.
NZ510931A1996-12-021997-12-02Polylactide-polyglycolide (PLGA) sustained release formula containing at least 50% active ingredient
NZ510931A
(en)
Method for the preparation of a pharmaceutical composition comprising 5-aminosalicyclic acid for use in treatment of ulcerative colitis and crohn's disease.
Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, the use thereof in the treatment of vascular diseases and pharmaceutical composition containing the compound as active ingredient